SETDB1 and neoplasm: SETDB1, a key epigenetic regulator, has emerged as a promising target in cancer treatment due to its role in silencing genes through H3K9me3 modifications and promoting oncogenic signaling through non‐histone protein methylation, contributing to tumor proliferation and resistance.